Devonian Health Group Inc. (CVE:GSD – Get Free Report) dropped 31.6% on Tuesday . The company traded as low as C$0.10 and last traded at C$0.13. Approximately 130,060 shares changed hands during trading, an increase of 603% from the average daily volume of 18,503 shares. The stock had previously closed at C$0.19.
Devonian Health Group Trading Down 31.6%
The business’s 50 day moving average is C$0.17 and its two-hundred day moving average is C$0.19. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The firm has a market capitalization of C$19.27 million, a P/E ratio of -6.50 and a beta of 1.28.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Lululemon, UNH, Enphase: Bad News, Good Opportunity?
- Best Aerospace Stocks Investing
- Applied Digital: Now the High-Stakes Race to Build Begins
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Zscaler Upgraded: Wall Street Forecasts 26% More Upside
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
